- Home
- CFBK vs FATE Comparison
CFBK vs FATE Comparison
Compare CFBK & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFBK
- FATE
- Stock Information
- Founded
- CFBK 1892
- FATE 2007
- Country
- CFBK United States
- FATE United States
- Employees
- CFBK N/A
- FATE N/A
- Industry
- CFBK Major Banks
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CFBK Finance
- FATE Health Care
- Exchange
- CFBK Nasdaq
- FATE Nasdaq
- Market Cap
- CFBK 127.9M
- FATE 134.1M
- IPO Year
- CFBK 1998
- FATE 2013
- Fundamental
- Price
- CFBK $23.95
- FATE $1.00
- Analyst Decision
- CFBK
- FATE Hold
- Analyst Count
- CFBK 0
- FATE 8
- Target Price
- CFBK N/A
- FATE $5.43
- AVG Volume (30 Days)
- CFBK 16.9K
- FATE 2.1M
- Earning Date
- CFBK 05-06-2025
- FATE 05-20-2025
- Dividend Yield
- CFBK 1.17%
- FATE N/A
- EPS Growth
- CFBK N/A
- FATE N/A
- EPS
- CFBK 2.27
- FATE N/A
- Revenue
- CFBK $47,766,000.00
- FATE $13,631,000.00
- Revenue This Year
- CFBK N/A
- FATE N/A
- Revenue Next Year
- CFBK N/A
- FATE N/A
- P/E Ratio
- CFBK $10.57
- FATE N/A
- Revenue Growth
- CFBK 1.43
- FATE N/A
- 52 Week Low
- CFBK $16.92
- FATE $0.66
- 52 Week High
- CFBK $31.17
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- CFBK 67.96
- FATE 44.85
- Support Level
- CFBK $23.25
- FATE $0.91
- Resistance Level
- CFBK $24.23
- FATE $1.20
- Average True Range (ATR)
- CFBK 0.44
- FATE 0.13
- MACD
- CFBK 0.12
- FATE -0.03
- Stochastic Oscillator
- CFBK 88.71
- FATE 18.75
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.